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Letter to the Editor
primary (37.0%) care settings. Remitted MDD patients and con-
trols were mainly recruited from primary care (54.8 and 21.6%) 
and the community (45.0 and 78.4%).
Common somatic diseases were assessed by a face-to-face inter-
view. Somatic disorders were considered present when participants 
reported a diagnosis of common specific somatic diseases and for 
which they reported to receive medical attention (i.e., under treat-
ment by a physician or receiving medication specifically for that 
reported somatic disease). We used somatic disease categories as 
categorized previously [7]: cardiometabolic, respiratory, musculo-
skeletal and digestive diseases, and cancer. An “any somatic disease” 
variable was created by combining the information from these so-
matic disease categories, and was dichotomized into “no onset of 
any somatic disease” (0) or “onset of ≥1 somatic diseases” (1).
The 30-item self-report Inventory of Depressive Symptomatol-
ogy (IDS), a reliable and valid instrument [8], was used to assess 
depression characteristics: overall depression severity (total IDS 
score, range 0–84), depressive symptom clusters (classification of 
30 individual IDS items into a mood, cognitive and somatic/veg-
etative cluster), and individual depressive symptoms (30 individ-
ual IDS items scored on a 0–3 (from not at all to severe) scale, and 
considered present when scored ≥2 (i.e., moderate or severe).
The 6-year incidence of any somatic disease and the somatic 
disease categories were compared between current and remitted 
MDD persons with controls in only those who were free of that 
particular somatic disease at baseline. Multivariable Cox regression 
analyses were used and adjusted for sociodemographics and life-
style. Also, the 6-year incidence of any somatic disease was further 
examined in relation to clinical depression characteristics in the 
total sample that was initially free of any somatic disease at baseline.
Current MDD patients had a significantly higher 6-year inci-
dence of any somatic disease (HR = 1.37, 95% CI = 1.06–1.77), 
cardiometabolic diseases (HR = 1.78, 95% CI = 1.21–2.60), mus-
culoskeletal diseases (HR = 1.74, 95% CI = 1.23–2.47) and digestive 
diseases (HR = 1.78, 95% CI = 1.20–2.64) than controls after ad-
justment for sociodemographics and lifestyle, but not of respira-
tory diseases (HR = 1.63, 95% CI = 0.95–2.80) and cancer (HR = 
1.07, 95% CI = 0.71–1.61) (see online suppl. Table S1). Remitted 
MDD persons versus controls showed increased somatic disease 
incidence risks, although they were nonsignificant. Analyses re-
stricted to only medication-confirmed somatic disease incidence 
(see online suppl. material) or with additional adjustment for an-
tidepressant use (data not shown) did not yield different results.
Within the entire sample that was initially free of any somatic 
disease (n = 1,327), higher overall depression severity predicted a 
higher 6-year incidence of any somatic disease in a dose-response 
manner (standardized total IDS score HR = 1.18, 95% CI = 1.04–
1.33), and a higher incidence of any somatic disease was associated 
with the mood symptom cluster (HR = 1.13, 95% CI = 1.02–1.25) 
and somatic/vegetative symptom cluster (HR = 1.18, 95% CI = 
1.07–1.31) in adjusted models (Fig. 1, see online suppl. Table S6). 
Dear Editor,
Major depressive disorder (MDD) is associated with excess on-
set of a multitude of somatic diseases, for instance cardiovascular 
diseases, diabetes and to a lesser extent cancer [1–3]. Since MDD 
plus somatic disease comorbidity increases the negative impact on 
public health, gaining insight into which depression characteristics 
contribute to the onset of somatic diseases is necessary. This may 
improve prevention strategies by targeting prevention to those 
with specific depression characteristics and pinpoint more spe-
cific innovative treatment targets, from which both depressed pa-
tients as well as society may greatly benefit. However, not many 
studies have examined the impact of different clinical depression 
characteristics on incidence risks of somatic diseases. Distinct de-
pressive subtypes may differ in underlying pathophysiology and 
subsequently may have a differential risk of somatic diseases [4]. 
This study examines whether the 6-year incidence of common so-
matic diseases differs between current and remitted MDD persons 
with healthy controls. Furthermore, the impact of MDD on so-
matic disease incidence was examined by exploring the role of clin-
ical depression characteristics (severity, symptom clusters, indi-
vidual symptoms and subtypes).
Baseline, 2-, 4- and 6-year follow-up data were used from the 
Netherlands Study of Depression and Anxiety, a longitudinal co-
hort study including 2,981 participants (aged 18–65 years) [5] 
(more details in the suppl. material; for all suppl. material, see 
www.karger.com/doi/10.1159/000491933). Eligible participants 
who had available data on at least 1 follow-up assessment (2-, 4-, 
6-year follow-up) were 968 current (6-month recency) MDD pa-
tients, 482 remitted (presence of lifetime MDD but without an 
MDD or anxiety disorder in the past 6 months) MDD patients and 
616 healthy controls (no lifetime depressive and anxiety disorder) 
at baseline, assessed using the DSM-IV-based Composite Interna-
tional Diagnostic Interview (CIDI, version 2.1) [6]. Recruitment of 
current MDD patients was mainly from specialized (54.6%) and 
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A higher incidence of any somatic disease was associated with the 
individual mood symptoms “diminished quality of mood” (HR = 
1.39, 95% CI = 1.10–1.76), “feeling irritable” (HR = 1.39, 95% CI = 
1.09–1.78) and “leaden paralysis” (HR = 1.37, 95% CI = 1.10–1.71) 
and the somatic/vegetative symptoms “aches and pains” (HR = 
1.81, 95% CI = 1.43–2.30), “constipation/diarrhea” (HR = 1.64, 
95% CI = 1.22–2.20), “other bodily symptoms” (HR = 1.60, 95% CI 
= 1.21–2.13) and “psychomotor agitation” (HR = 1.30, 95% CI = 
1.03–1.64). When examining MDD subtypes, we could not con-
firm that MDD patients with or without anxious distress and those 
with atypical versus melancholic symptoms did differ in the inci-
dence of somatic diseases (see online suppl. Table S7). 
Our finding of current MDD increasing the 6-year incidence of 
a multitude of common somatic diseases is in line with previous 
research [1, 2]. That remitted MDD persons also had increased 
somatic disease incidence risks albeit nonsignificant ones, is in line 
with our finding of a dose-response relationship between overall 
depression severity and somatic disease incidence, suggesting that 
possible residual depressive symptoms in remitted MDD persons 
are contributing to the incidence of somatic diseases. One study 
also found that current but not remitted depression is a strong pre-
dictor for all-cause mortality after adjustment for cardiovascular 
and lifestyle factors which indicate that the effect of depression 
decreases after remission, possibly due to an increased vulnerabil-
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Fig. 1. Adjusted hazard ratios for 6-year incidence of any somatic 
disease by IDS depression severity, symptom clusters and indi-
vidual symptoms within the total sample that was initially free of 
any somatic disease (n = 1,327). CI, confidence interval; IDS, In-
ventory of Depressive Symptomatology; HR, hazard ratio; MDD, 
major depressive disorder; the triangle represents total IDS score, 
circles represent depressive mood symptoms, diamonds represent 
depressive cognitive symptoms, and squares represent depressive 
somatic/vegetative symptoms. Based on Cox regression analyses. 
Adjusted for sociodemographics (age, sex, education) and lifestyle 
(smoking status, alcohol intake, physical activity and body mass 
index). Total IDS score and IDS symptom clusters were standard-
ized; IDS items were dichotomized. Error bars represent 95% CIs. 





ity of persons with a current depressive episode and potential re-
silience of persons who achieved remission [9]. Current MDD pa-
tients may also have a greater sensibility to somatic symptoms and 
make use of health care more often than those with remitted MDD, 
possibly resulting in a higher somatic disease incidence in cur-
rently depressed patients. 
Our finding that somatic/vegetative depressive symptoms 
seem to contribute to a higher somatic disease incidence is in line 
with a meta-analysis showing that in patients with heart disease, 
somatic depressive symptoms were associated with cardiovascular 
prognosis, unlike cognitive depressive symptoms [10]. Possibly, 
some of these somatic/vegetative symptoms may be prodromal 
symptoms of a somatic disease instead of actual depressive symp-
toms, which may lead to an overestimation of the found associa-
tion between somatic/vegetative symptoms and somatic disease 
incidence. Several mood symptoms were associated with a higher 
onset risk of somatic diseases. An explanation may be lower self-
care due to mood symptoms which will ultimately lead to somatic 
disease developments. Future research should examine by which 
mechanisms somatic/vegetative and mood depressive symptoms 
may contribute to higher somatic disease onset risks, to inform 
tailored prevention or treatment strategies.
To conclude, having current MDD increases subsequent onset 
risks of a multitude of somatic diseases, which was not restricted to 
one single disease category (cardiometabolic, musculoskeletal and 
digestive diseases, but not of respiratory diseases and cancer). Per-
sons with remitted MDD also showed increased 6-year incidence 
rates of somatic diseases, albeit nonsignificant ones. Depressive 
subtypes did not differ in their somatic disease incidence risks as 
compared to controls. Higher depression severity showed a dose-
response relationship with higher somatic disease incidence. De-
pressive subtypes (i.e., MDD with anxious distress, atypical or mel-
ancholic features) did not substantially differ in their somatic dis-
ease incidence risks. However, both mood and somatic/vegetative 
depressive symptom dimensions seemed to contribute to higher 
somatic disease onset risks. Our results suggest that current MDD 
patients, specifically those with high depression severity, and mood 
and somatic/vegetative symptoms should be monitored more 
closely and routinely screened on somatic disease comorbidity.
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